A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

NCT05773040 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Lymphomas
B-cell Lymphomas

Interventions

DRUG: JV-213
PROCEDURE: Leukapheresis

Sponsor

M.D. Anderson Cancer Center